HX008 + niraparib + pyrrolitinib

This is a **combination investigational regimen** composed of three agents: - **HX008**, a monoclonal antibody targeting the programmed death 1 (**PD-1**) receptor for immune checkpoint inhibition - **Niraparib**, a small molecule inhibitor of **poly (ADP-ribose) polymerase (PARP)**, approved for ovarian cancer and other indications as maintenance or combination therapy - **Pyrrolitinib** (also known as pyrotinib), a small molecule irreversible inhibitor that targets **epidermal growth factor receptor (EGFR)** and **human epidermal growth factor receptor 2 (HER2)** tyrosine kinases, typically used in HER2-positive cancers The combination is under investigation predominantly in advanced or metastatic breast cancer characterized by deficiencies in DNA damage response (DDR) genes, including BRCA1/2, and potentially other solid tumors. The goal is to leverage **immune checkpoint blockade**, **DNA repair inhibition**, and **HER/EGFR pathway inhibition** for synergistic anti-tumor effects.

Brand names

Zejula